These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32216035)

  • 1. A critical review of graphics for subgroup analyses in clinical trials.
    Ballarini NM; Chiu YD; König F; Posch M; Jaki T
    Pharm Stat; 2020 Sep; 19(5):541-560. PubMed ID: 32216035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.
    Yip WK; Bonetti M; Cole BF; Barcella W; Wang XV; Lazar A; Gelber RD
    Clin Trials; 2016 Aug; 13(4):382-90. PubMed ID: 27094489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
    Lazar AA; Bonetti M; Cole BF; Yip WK; Gelber RD
    Clin Trials; 2016 Apr; 13(2):169-79. PubMed ID: 26493094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple uses of forest plots in presenting analysis results in health research: A Tutorial.
    Li G; Zeng J; Tian J; Levine MAH; Thabane L
    J Clin Epidemiol; 2020 Jan; 117():89-98. PubMed ID: 31589955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graphics and Statistics for Cardiology: Data visualisation for meta-analysis.
    Kiran A; Crespillo AP; Rahimi K
    Heart; 2017 Jan; 103(1):19-23. PubMed ID: 27810865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graphic report of the results from propensity score method analyses.
    Shrier I; Pang M; Platt RW
    J Clin Epidemiol; 2017 Aug; 88():154-159. PubMed ID: 28603009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization for subgroup analysis in randomized controlled trials.
    Varadhan R; Wang SJ
    J Biopharm Stat; 2014; 24(1):154-67. PubMed ID: 24392983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and analysis of prostate cancer trials.
    Sylvester R
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graphical Presentation of Patient-Treatment Interaction Elucidated by Continuous Biomarkers. Current Practice and Scope for Improvement.
    Shen YM; Le LD; Wilson R; Mansmann U
    Methods Inf Med; 2017 Jan; 56(1):13-27. PubMed ID: 27782287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
    Hemmings R
    J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graphical displays for meta-analysis: An overview with suggestions for practice.
    Anzures-Cabrera J; Higgins JP
    Res Synth Methods; 2010 Jan; 1(1):66-80. PubMed ID: 26056093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More than numbers: the power of graphs in meta-analysis.
    Bax L; Ikeda N; Fukui N; Yaju Y; Tsuruta H; Moons KG
    Am J Epidemiol; 2009 Jan; 169(2):249-55. PubMed ID: 19064649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials.
    Chen J; Zheng H; Quan H; Li G; Gallo P; Ouyang SP; Binkowitz B; Ting N; Tanaka Y; Luo X; Ibia E;
    Clin Trials; 2013; 10(6):842-51. PubMed ID: 24013404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The orchard plot: Cultivating a forest plot for use in ecology, evolution, and beyond.
    Nakagawa S; Lagisz M; O'Dea RE; Rutkowska J; Yang Y; Noble DWA; Senior AM
    Res Synth Methods; 2021 Jan; 12(1):4-12. PubMed ID: 32445243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis.
    Langan D; Higgins JP; Gregory W; Sutton AJ
    J Clin Epidemiol; 2012 May; 65(5):511-9. PubMed ID: 22342263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.
    Bonetti M; Zahrieh D; Cole BF; Gelber RD
    Stat Med; 2009 Apr; 28(8):1255-68. PubMed ID: 19170050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How subgroup analyses can miss the trees for the forest plots: A simulation study.
    Webster-Clark M; Baron JA; Jonsson Funk M; Westreich D
    J Clin Epidemiol; 2020 Oct; 126():65-70. PubMed ID: 32565216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contour plot assessment of existing meta-analyses confirms robust association of statin use and acute kidney injury risk.
    Chevance A; Schuster T; Steele R; Ternès N; Platt RW
    J Clin Epidemiol; 2015 Oct; 68(10):1138-43. PubMed ID: 26092287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.